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Striatal cell death in Huntington’s Disease (HD) may involve mitochondrial defects, NMDA-mediated excitotoxicity, and activation of
death effector proteases such as caspases and calpain. However, the precise contribution of mitochondrial defects in the activation of
these proteases in HD is unknown. Here, we addressed this question by studying the mechanism of striatal cell death in rat models of HD
using the mitochondrial complex II inhibitor 3-nitropropionic acid (3-NP). The neurotoxin was either given by intraperitoneal injections
(acute model) or over 5 d by constant systemic infusion using osmotic pumps (chronic model) to produce either transient or sustained
mitochondrial deficits. Caspase-9 activation preceded neurodegeneration in both cases. However, caspase-8 and caspase-3 were acti-
vated in the acute model, but not in the chronic model, showing that 3-NP does not require activation of these caspases to produce striatal
degeneration. In contrast, activation of calpain was specifically detected in the striatum in both models and this was associated with a
calpain-dependent cleavage of huntingtin. Finally, in the chronic model, which mimics a steady blockade of complex II activity reminis-
cent of HD, selective calpain inhibition prevented the abnormal calpain-dependent processing of huntingtin, reduced the size of the
striatal lesions, and almost completely abolished the 3-NP-induced DNA fragmentation in striatal cells. The present results demonstrate
that calpain is a predominant effector of striatal cell death associated with mitochondrial defects in vivo. This suggests that calpain may
play an important role in HD pathogenesis and could be a potential therapeutic target to slow disease progression.
Key words: neurodegenerative disease; excitotoxicity; mitochondrial complex II inhibitor; calpain; caspase; calpain inhibitor;
neuroprotection
Introduction
Huntington’s disease (HD) is a genetic disorder associated with
severe motor and cognitive deficits and preferential degeneration
of medium spiny GABAergic neurons located in the striatum
(Harper, 1991). Whereas the genetic defect responsible for HD is
identified as an expansion of polyglutamine sequences within the
huntingtin (Htt) protein (Huntington’s Disease Collaborative
Research Group, 1993), most of the pathological mechanisms
linking the mutant protein to the selective neurodegeneration
observed in the patient’s brain remain highly speculative.
Mechanisms of cell death specifically implicated in HD patho-
genesis include oxidative stress, mitochondrial defects, excitotox-
icity, and activation of death effector proteases. The mitochon-
drial defects most consistently found in HD involve the succinate
dehydrogenase-complex II and Ca 2 homeostasis (Gu et al.,
1996; Browne et al., 1997; Tabrizi et al., 1999; Panov et al., 2002).
Compelling evidence also supports the view that excitotoxic cell
death plays a major role in HD (DiFiglia, 1990). This is further
supported by more recent observations of transgenic mice over-
expressing full-length mutated Htt in which striatal neurons dis-
play increased NMDA-evoked currents and are more vulnerable
to the toxic effects of the NMDA-receptor agonist quinolinate
(Cepeda et al., 2001; Laforet et al., 2001; Zeron et al., 2002).
Finally, a central role in the toxicity of the mutant form of Htt of
the proteases of the caspase family (Saudou et al., 1998; Sanchez
et al., 1999; Wellington et al., 2002) and more recently of the
Ca 2-activated neutral protease calpain (Kim et al., 2001; Gafni
and Ellerby, 2002) has also been suggested. Despite this accumu-
lating data, the precise contribution of these cell death mecha-
nisms in HD pathogenesis is still unknown. A sequential process
of cell death has been hypothesized for HD in which mitochon-
drial defects lead indirectly to excitotoxicity, activation of cell
death effector proteases, and eventually cell demise (Albin and
Greenamyre, 1992; Beal, 1992). An alternative mechanism pro-
poses that all these steps are part of a self-amplifying vicious circle
in which they are either initiated by, or themselves contribute to,
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an impairment of mitochondrial function leading to energy fail-
ure and ultimately cell death (for review, see Petersen et al., 1999).
In support of the sequential process, experimental mitochondrial
blockade using the selective complex II inhibitors malonate or
3-nitropropionic acid (3-NP) has shown that mitochondrial per-
turbation by itself can trigger NMDA receptor activation leading
to selective degeneration of the striatal medium spiny GABAergic
neurons (Brouillet et al., 1999). Whether the mitochondrial de-
fects in HD mimicked by malonate and 3-NP are also directly
responsible for the preferential activation of caspases and/or cal-
pains in vivo is unknown.
To address this question, we used 3-NP-mediated succinate
dehydrogenase (SDH) inhibition in rats as a mean to produce
either transient (acute model) or sustained (chronic model) mi-
tochondrial deficits and characterized the pattern of caspase and
calpain activation, in relation to these different patterns of mito-
chondrial perturbation. We found evidence for a regionally re-
stricted calpain activation in both models in vivo. We then exam-
ined whether inhibiting calpain in vivo could also specifically
protect the striatum in the chronic model of mitochondrial
blockade.
Materials and Methods
Animals. We used 12-week-old male Lewis rats (Iffa Credo, L’Arbresle,
France) weighing 340 –370 gm. All experimental procedures were per-
formed in strict accordance with the recommendations of the European
Community (86/609/EEC) and the French National Committee
(87/848) for care and use of laboratory animals.
All chemicals and reagents were purchased from Sigma (L’Isle d’Abeau
Chesnes, France) unless specified otherwise.
3-NP treatment and experimental design. Two different 3-NP-rat mod-
els were studied.
In the chronic model, a solution of 3-NP was delivered by chronic
infusion (54 mg  kg1  d1) using osmotic minipumps (flow rate 10
l/hr, model 2ML1; Alzet, Palo Alto, CA) placed subcutaneously in the
back of the animals under ketamine–xylazine anesthesia (Dautry et al.,
2000; Garcia et al., 2002; Mittoux et al., 2002; Blum et al., 2002). Control
rats were sham-operated. In a first experiment, animals (5– 6 per time
point) were killed every 6 hr from day 2 to day 5 for biochemical analysis
(DNA fragmentation, caspase-3-related proteolytic activity, fodrin
cleavage) and immunohistochemistry (caspase-3, -8, -9). In this experi-
ment including 65 3-NP-treated rats, survival was 100%. In a second
experiments in which animals were analyzed for activation of caspase-3,
-8 and -9 and calpains by Western blot and proteolytic activity assays,
groups of rats (n  5– 8) were killed by decapitation at daily intervals
(days 1, 2, 3, 4, and 5) after osmotic pump implantation (day 0). In this
experiment including 35 3-NP-treated rats, one animal of the day 5
group (n 7) died prematurely and could not be analyzed. All animals
chronically treated with 3-NP were included in biochemical analysis.
In the acute model, animals received two intraperitoneal injections of
3-NP (25 mg/ml, pH 7.4, 50 mg/kg) at 90 min intervals. Control animals
received intraperitoneal injections of saline. Animals were killed at 3, 6,
12, 24, and 48 hr after the first intraperitoneal injection of the neuro-
toxin. Rats showed variable responses to this acute 3-NP regimen. In the
experiments presented, survival rate over the 48 hr after injection was
87% (time point, n survivor/n per group: 6 hr, 7/7; 12 hr, 7/7; 24 hr, 8/10;
48 hr, 11/14). All rats of the 6 hr group were used for analysis. For later
time points, only rats with obvious uncoordination and/or dystonia
among survivors were taken for analysis (time point, n symptomatic/n
survivors: 12 hr, 7/7; 24 hr, 5/8; 48 hr, 10/11).
Calpain inhibitor I neuroprotection experiments in the chronic model.
The calpain inhibitor I (CI-1; z-Leu-Leu-Norleucinal; Biomol, Plymouth
Meeting, PA) solubilized in phosphate buffer saline containing 40% di-
methylsulfoxide was delivered (2.5 g/hr, 1 l/hr) by intracerebroven-
tricular infusion using an osmotic minipump (model 2001; Alzet) con-
nected to a stereotaxically implanted cannula [anteroposterior (AP) –1.6
mm, lateral 2.0 mm from bregma, ventral 3.5 mm from dura, using the
“brain infusion kit”; Alzet]. The minipump delivering 3-NP and that
delivering CI-1 were implanted simultaneously. Histological and bio-
chemical evaluation was performed on day 5 of the neurotoxic treatment.
Brain processing, sample dissection, and homogenization. Brains were
rapidly removed from the skull and cut vertically along the rostrocaudal
axis into two hemispheres. The left hemisphere was fixed in Bouin’s
solution for 3 d and paraffin-embedded for immunohistochemical eval-
uation. For CI-1 studies, the left hemisphere was frozen in isopentane
(30°C) and stored at – 80°C for histological evaluation. Striatum and
cortex samples were dissected and processed for biochemical analyses
from the right hemisphere. Tissue dissection was carried out on an ice-
cooled platform. The lateral striatum and the surrounding cerebral cor-
tex were dissected out from coronal slices (2-mm-thick) (Dautry et al.,
2000). Tissue samples (10 –20 mg) were homogenized using a 1 ml glass
Teflon potter (900 rpm, 20 strokes) in 300 l of ice-cooled buffer con-
taining 25 mM HEPES-KOH, pH 7.4, 0.1% Triton X-100, 5 mM MgCl2,
1.3 mM EDTA, 1 mM EGTA, and proteases inhibitor cocktail (Roche,
Meylan, France) (Namura et al., 1998). Homogenates were centrifuged at
15,000 g for 30 min. The supernatant (soluble fraction) and the pellet
(membrane fraction) were stored at – 80°C until analysis.
Western blot analysis. Protein concentrations were determined using
the BCA method (Pierce, Rockford, IL) according to the manufacturer’s
instructions. Proteins in striatal and cortical fractions were separated by
SDS-PAGE as previously described (Hermel et al., 1999). After blot
transfer, nitrocellulose membranes were incubated overnight at 4°C with
one of the antibodies raised against fodrin (1:2000, antibody against
non-erythroid -spectrin; Chemicon, Temecula, CA), huntingtin
[1:1000; 4C8 clone, antibody (Ab) 2166; Euromedex, Souffelweyersheim,
France], caspase-9 (1:1000; Bur 81 and Bur 73, Krajewski et al., 1999),
caspase-8 (1:1000; Bur 1890, Stoka et al., 2001), caspase-3 (1:1000; Ab
1797; Cell Signaling Technology, Beverly, MA) and -calpain (1:1000;
domain III, clone 9A4H8D3, Biomol). The blots were incubated with
horseradish peroxidase-conjugated anti-mouse or anti-rabbit IgG
(1:1000, Sigma), and peroxidase activity was detected using ECL reagent
(Pierce).
Immunohistochemistry and histological studies. Caspase-9, -8, and -3
immunohistochemistry and Masson-trichrome staining was performed
on paraffin sections as previously described (Krajewski et al., 1999; Stoka
et al., 2001). The antibodies used for immunohistochemistry of caspases
were similar to those used for Western blot. For neuroprotection studies,
lesion severity was evaluated on frozen coronal sections (40-m-thick).
Cells with DNA fragmentation were detected by the terminal deoxynu-
cleotidyl transferase-mediated biotinylated UTP nick end labeling
(TUNEL) method using the “In situ cell death detection-fluorescein kit”
(Roche) (Dautry et al., 2000; Ouary et al., 2000). For each animal, cells
were counted over the entire surface of the striatum in one section at the
same rostrocaudal level (AP 0.5 mm) with a 20 objective (350 fields
of view per section) using an automated motorized stage and acquisition
system (Fluovision; IMSTAR, Paris, France). SDH and cytochrome oxi-
dase (COX) histochemistry was performed and quantitatively analyzed
as previously described (Greene and Greenamyre, 1995; Brouillet et al.,
1998).
Oligonucleosome detection. Oligonucleosome contents in soluble frac-
tions (20 l) were determined using the “ELISA cell death detection kit”
(Roche) according to the manufacturer instructions. The results were
normalized by the protein concentrations in each sample and expressed
as mean OD values SEM.
Proteolytic activity assay using fluorogenic substrate for caspases and calpain.
The fluorescent assay of the protease activity is based on the cleavage of
7-amino-4-methyl-coumarin (AMC) or 7-amino-4-trifluoro-methyl-
coumarin (AFC) dyes from the C terminus of the peptide substrates. The
calpain activity was determined using N-succinyl-Leu-Tyr-(N-succinyl-
LY)-AMC, a substrate preferentially cleaved by/m-calpain (McDonald
et al., 2001). Calpain activity (Ca 2-dependent cleavage of N-succinyl-
LY-AMC) present in brain sample supernatants (10l containing30
g of protein) was determined as the difference between the calcium-
dependent and the non-calcium-dependent fluorescence. The calcium-
dependent fluorescence released was measured after 30 min incubation
at 37°C in buffer A containing 63 mM imidazol-HCl, pH 7.3, 10 mM
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-mercaptoethanol, and 5 mM CaCl2 and is attributable to the cleavage of
150M N-succinyl-LY-AMC. The non-calcium-dependent fluorescence
was measured under the same conditions using buffer A without calcium
and containing 1 mM EDTA and 10 mM EGTA. To measure the inhibiting
effects on calpain activity of striatal samples from animals treated in vivo
with CI-1 or its vehicle, 10 l of supernatant was incubated in 90 l of
calpain assay buffer containing purified -calpain (0.2 U; Calbiochem).
Caspase-3, -8, and -9 activities were tested on peptidic substrates (Bi-
omol), using respectively N-acetyl-Asp-Glu-Val-Asp-AFC (DEVD-
AFC), N-acetyl-Ile-Glu-Thr-Asp-AFC (IETD-AFC), and N-acetyl-Leu-
Glu-His-Asp-AFC (LEHD-AFC). Soluble fractions (30 g of protein)
were incubated at 37°C for 45 min in a caspase buffer B (in mM: 20
HEPES, pH 7.4, 50 NaCl, 0.2 EDTA, and 4 DTT) with 40 M of the
appropriate substrate. The nonspecific activity was considered as the
activity remaining in the presence of the fluorogenic substrate and 10M
of the appropriate caspase inhibitor i.e., the C-terminal aldehyde form
(CHO) of the substrate (DEVD-CHO, IETD-CHO, and LEHD-CHO for
caspase-3, -8, and –9, respectively). Fluorescence (excitation/emission:
400/505 nm for AFC and 380/460 nm for AMC) was measured in 96 well
plates using a “Fusion” fluorimeter (Packard Bioscience, Rungis,
France). Enzyme activity was calculated using standard curves of AFC or
AMC and expressed as mean activity (picomoles of AFC–AMC released
per minute per milligram of protein) SEM.
Calpain-induced cleavage of fodrin and huntingtin in vitro. The in vitro
proteolysis of endogenous fodrin and huntingtin was studied after incu-
bation (1 hr at 37°C) of control samples (20 g of protein) with purified
-calpain (0.2 U; Calbiochem) or recombinant caspase-3 (50 ng; Bi-
omol) in 100 l of the assay buffer A or B, respectively. Digestion prod-
ucts were analyzed by SDS-PAGE (8 –20% gradient gel) followed by
Western blot analysis.
Statistical analysis. Results were expressed as means SEM. Statistical
analysis included Student’s t test or one-way ANOVA followed by a post
hoc Scheffe´ F test.
Results
Time course of striatal degeneration and primary
mitochondrial impairment in acute and chronic 3-NP models
In the acute model, all 3-NP-treated rats showed symptoms of
drowsiness, slowness of movement, and general uncoordination
at 6 hr. Histological evaluation indicated that 43% (3/7) of these
animals had striatal lesions. Uncoordination and bradykinesia
were more pronounced at 12 hr. At this time point, 71% (5/7) of
the animals showed tissue abnormalities, including shrinkage of
medium neurons and edema in the striatum (data not shown).
After 24 – 48 hr, symptomatic rats had developed severe and per-
manent dystonia of hindlimbs or recumbency. In these rats, the
entire lateral striatum was lesioned with many cells displaying
fragmented nuclei or condensed chromatin (Fig. 1B,E). Consis-
tent with this, biochemical analysis showed evidence of nuclear
damage in these animals with a significant 20-fold increase in free
oligonucleosome levels (an index of DNA fragmentation) com-
pared with control levels (Fig. 2). Thus in the acute model, the
onset of striatal lesion was about 6 hr after 3-NP injection and the
bulk of degeneration occurred within 24 hr of the 3-NP
administration.
In the chronic model, motor symptoms were prominent on
day 4 in all treated rats and worsened on day 5 as previously
described (Ouary et al., 2000; Garcia et al., 2002; Mittoux et al.,
2002). Histological evaluation of the 3-NP-treated animals (n 6
per time point) at day 3, day 3 plus 6 hr, day 3 plus 12 hr, and day
3 plus 18 hr did not show any striatal abnormalities. At day 4,
37.5% (6/16) of the animals showed small lesions in the dorso-
lateral aspect of the striatum. This was associated with a sevenfold
increase in free oligonucleosome levels compared with controls
(Fig. 2). At day 4 plus 6 hr, day 4 plus 12 hr, day 4 plus 18 hr, and
day 5, all rats (n 6 per group) showed striatal lesions. At day 5,
the entire lateral part of the striatum was lesioned (Fig. 1C,F), and
free oligonucleosome levels were increased 28-fold (Fig. 2). This
shows that the onset of lesion was a few hours before day 4, and
aggravation of striatal cell death occurred within the next 24 –30
hr. Thus, progression of obvious striatal cell death was relatively
similar in both models.
The primary effect of 3-NP is the irreversible inhibition of the
catalytic site of SDH, the main component of mitochondrial
complex II (Brouillet et al., 1999). One important characteristic
Figure 1. 3-NP-induced preferential degeneration and cell death in the striatum. Sagittal
brain sections (Masson-trichrome staining) in control (A, D), acute (B, E), and chronic (C, F ) 3-NP
models. A–C, Sections of the entire brain at low magnification at two different lateral levels
showing the striatal lesion as a pale staining (B, C, arrows). D–F, High magnification of the
striatum. Representative normal nuclear staining and the perikarya (devoid of staining, open
arrow) of striatal cells (mainly projection neurons) in a control animal is shown in D. Abnormal
chromatin condensation and cytoplasm reduction (arrowhead) in neurons is observed in the
dorsolateral striatum at 24 hr after acute 3-NP injections ( E) and on day 5 in the chronic model
( F). Scale bars, 10m.
Figure 2. Evolution of nuclear DNA fragmentation in the striatum in the acute (open bars)
and chronic (black bars) 3-NP models. What is shown is relative changes of free oligonucleo-
somes (i.e., an index of DNA fragmentation due to ongoing cell death) measured in the soluble
fraction of striatal homogenates. Each bar corresponds to the mean value SEM determined in
6 –10 animals.p 0.0001 compared with control, ANOVA, and post hoc Scheffe´ F test.
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of the 3-NP lesion model of HD is that although 3-NP inhibits
striatal and extrastriatal (i.e., cerebral cortex) SDH activity to
similar extent, the toxin produces a striatal degeneration with
sparing of the cerebral cortex. Thus, region-selective neurode-
generation is not associated with a given levels of SDH inhibition
in the brain (Brouillet et al., 1998; Garcia et al., 2002). Therefore,
the loss of SDH activity in the cortex reflects solely 3-NP-induced
inhibition of SDH, whereas in the striatum it reflects 3-NP block-
ade plus the loss of SDH containing neurons (Brouillet et al.,
1998; Garcia et al., 2002). To estimate the levels of SDH inhibition
in the striatum caused solely by 3-NP-induced blockade of the
enzyme, we measured SDH activity in the cortex.
In the acute model, cortical SDH activity was inhibited by 40%
after 3– 6 hr (Fig. 3). This SDH inhibition decreased at 12 hr so
that SDH activity was at 80% of control and remained at this level
up to 48 hr after 3-NP injection. These data show that in an acute
experimental paradigm, 3-NP produces a “transient” peak effect
on oxidative energy metabolism (Fig. 3).
In marked contrast, in the chronic model, SDH activity was
progressively inhibited, decreasing by 60 –70% on days 3–5 (Fig.
3). These data indicate that very different patterns of SDH inhi-
bition can be achieved depending on the systemic administration
of the mitochondrial toxin and that only the chronic model is
associated with a sustained 60 –70% inhibition of complex II
reminiscent of that seen in HD.
Differential patterns of caspase activation are found in acute
and chronic models of mitochondrial blockade
After acute administration of 3-NP, in the striatum, caspase-9-
related LEHDase activity (Fig. 4A) showed a significant increase
at 12 hr compared with controls, and Western blot analysis
showed accumulation of the processed p34 subunit of caspase-9
(Fig. 4B). Consistent with this finding, immunohistochemistry
of active caspase-9 showed labeled cells in the striatum (Fig. 4C).
Caspase-8-related IETDase activity (Fig. 5A) was also signifi-
cantly increased at 12 hr, and an increase in the processing of
caspase-8 was observed by Western blot (Fig. 5B) and immuno-
histochemistry (Fig. 5C). In the same animals, significant in-
crease in striatal caspase-3-related DEVDase proteolytic activity
was detected at 24 hr (Fig. 6A). The presence of processed
caspase-3 in the striatum was also demonstrated by Western blot
analysis for the active form p17/19 (Fig. 6B). Accumulation of the
processed form of caspase-3 in degenerating striatal cells was
detected by immunohistochemistry at 12 and 24 hr (Fig. 6C). In
summary, the acute model was associated with increased process-
ing of both initiator and effector caspases.
During chronic 3-NP administration, a transient increase in
caspase-9-related LEHDase proteolytic activity was detected
within the striatum at day 3 (Fig. 4A). Western blot and immu-
nohistochemical analysis of the active form of caspase-9 also
showed an accumulation of the processed form of caspase-9 (Fig.
4B,C). Caspase-8-related IETDase activity was not increased in
the chronic model (Fig. 5A). Consistent with this, Western blot
analysis and immunohistochemistry showed no detectable accu-
mulation of the active caspase-8 subunit p20 (Fig. 5B,D). Simi-
Figure 3. 3-NP-induced inhibition of cortical SDH activity in the acute and chronic models. In
the chronic model, SDH inhibition reaches65% on day 3 and remains constant thereafter.
Note that in the acute model, SDH inhibition peaks at 6 hr after injection of the neurotoxin and
remains at low level thereafter. Each point corresponds to the mean value SEM in six or seven
animals. SDH inhibition was significant ( p0.01 compared with control, ANOVA, and post hoc
Scheffe´ F test) at all time points considered.
Figure 4. Study of caspase-9 in rats after acute or chronic 3-NP treatment. A, Caspase-9-
related LEHDase proteolytic activity in cerebral cortex and striatum. B, Analysis of striatal and
cortical samples by SDS-PAGE followed by Western blot for the active form of caspase-9. Re-
combinant caspase-9 (Casp.9) was loaded in the left lane as a positive control. Note that accu-
mulation of the p34 subunit of the active form of caspase-9 is detected in the striatum in the
acute and chronic 3-NP models. C, Immunohistochemistry of active caspase-9 showing low
levels of immunoreactivity in the striatum of control rats, whereas a marked increased labeling
(arrows) is detected in the acute model at 12 hr and in the chronic model at day 3. Data are
means SEM determined in 5–10 animals. N.D., Not detectable.p 0.001 compared with
control, ANOVA, and post hoc Scheffe´ F test.
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larly, there was no significant increase in caspase-3-related DEV-
Dase activity in the same animals (Fig. 6A) or evidence of
increased caspase-3 processing as seen by Western blot analysis
using an antibody selective for the p17/19 subunits of active
caspase-3 (Fig. 6C). This absence of increase in DEVDase activity
was observed in three independent experiments. To detect a pos-
sible transient activation of caspase-3 in the chronic model, a
group of rats was analyzed every 6 hr from day 2 to day 5. Again,
we found no change in DEVDase activity compared with control
in this group. Immunohistochemical evaluation of active
caspase-3 in these animals showed only a few scattered immuno-
reactive neurons in the striatum at day 4 (Fig. 6C).
Interestingly, in the cerebral cortex, which is not sensitive to
3-NP toxicity but in which SDH is similarly inhibited as in the
striatum, the same acute and chronic 3-NP rats showed no sig-
nificant change in DEVDase, LEHDase, and IETDase activity
(Fig. 4 – 6A). Consistently, Western blot analysis showed no
bands corresponding to active caspase-9, -8, and -3 in the cere-
bral cortex of 3-NP-treated rats (Fig. 4 – 6B).
3-NP-induced mitochondrial complex II defect is associated
with calpain activation
To further characterize the mechanism of cell death involved in
striatal degeneration associated with complex II defect in vivo, we
studied the pattern of cleavage of fodrin (non-erythroid
-spectrin) in the two models of mitochondrial defects. Fodrin is
a known substrate of caspase-3 as well as of the calcium-activated
neutral proteases, - and m-calpain (Wang, 2000). Importantly,
caspase-3-mediated cleavage of fodrin leads to 150 and 120 kDa
breakdown products, whereas calpain-mediated cleavage results
in a doublet near 145/150 kDa (Wang, 2000). In the acute model,
a specific calpain-dependent cleavage of fodrin leading to accu-
mulation of the 145/150 kDa products was detected at 12 hr in the
striatum (Fig. 7A). The intensity of the 145/150 kDa doublet
Figure 5. Study of caspase-8 in rats after acute or chronic 3-NP treatment. A, Caspase-8-
related IETDase proteolytic activity in striatal and cortical homogenates. B, Analysis of brain
samples by SDS-PAGE followed by Western blot for the active form of caspase-8. Recombinant
caspase-8 (Casp.8) was loaded in the left lane as a positive control. Note that accumulation of
the p20 subunit of the active form of caspase-8 is detected only in the striatum in the acute 3-NP
model at 12 hr. Ten micrograms of proteins were loaded per lane. C, Immunohistochemical
analysis of caspases-8 showing low levels of immunoreactivity in the striatum in control and
chronic model, whereas increased striatal labeling is observed in the acute model (arrows). Data
are means SEM determined in 5–10 animals. N.D., Not detectable.p 0.02 compared
with control, ANOVA, and post hoc Scheffe´ F test.
Figure 6. Study of caspase-3 in rats after acute or chronic 3-NP treatment. A, Caspase-3-
related DEVDase proteolytic activity in striatal and cortical homogenates. B, Analysis by SDS-
PAGE followed by Western blot for the active form of caspase-3. Recombinant caspase-3
(Casp.3) was loaded in the left lane as a positive control. Note that accumulation of the p20
subunit of the active form of caspase-3 (seen as a 17/19 kDa doublet) is detected only in the
acute 3-NP model at 48 hr. Ten micrograms of protein were loaded per lane. C, Immunohisto-
chemical analysis of activated caspases-3 showing low levels of immunoreactivity in the stria-
tum in control and chronic model, whereas marked increased striatal labeling in detected in the
acute model (arrows). N.D., Not detectable. Data are means SEM determined in 5–10 ani-
mals.p 0.0001 compared with control, ANOVA, and post hoc Scheffe´ F test.
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further increased at 24 hr, then disappeared at 48 hr. There was
also a low concentration of the 120 kDa breakdown product,
possibly because of caspase-3-mediated cleavage (Fig. 7A).
Chronic 3-NP intoxication resulted in a specific calpain-
dependent cleavage of fodrin in the striatum and not in the cere-
bral cortex (Fig. 7B,C). This was evident as a progressive and
selective accumulation of the 145/150 kDa fodrin breakdown
products on day 4. Accumulation was maximal at day 5 (Fig.
7A,B). No caspase-3-mediated 120 kDa breakdown product was
observed at this time point (Fig. 7C).
To assess the proteolytic activity of calpain in striatum and
cerebral cortex more directly, we measured the Ca 2-dependent
cleavage of N-succinyl-LY-AMC, a fluorogenic substrate cleaved
by calpain, in both models. In the acute model, contrary to West-
ern blot results above, we did not detect any increase in calpain
activity at 6, 12, 24, and 48 hr (Fig. 7D). This apparent discrep-
ancy might be explained by a short-lived activation of this en-
zyme between 6 and 12 hr, leading to the accumulation of
calpain-mediated breakdown products of fodrin detected in the
striatum at 12 and 24 hr. In the chronic model, calpain activity
was prominently increased i.e., 7- to 10-fold, at days 4 and 5 (Fig.
7D) in the striatum, consistent with the accumulation of the fo-
drin 145/150 kDa doublet.
We analyzed the expression and potential cleavage of
-calpain by Western blot. In the chronic model, we found an
intense 76/78 kDa doublet corresponding to the cleaved/active
form of-calpain at day 4 (Fig. 7E). Using the same Western blot
conditions, this cleaved form of -calpain was not found in the
striatum in the acute model (Fig. 7E), consistent with a probable
short-lived activation of the protease in this model.
Taken together, these results indicate pathological activation
of calpains (including -calpain) in the acute and chronic 3-NP
models. Interestingly, this activation was specific to the striatum:
no increased calpain proteolytic activity (Fig. 7D), no cleavage of
-calpain (Fig. 7E), and no modification of fodrin cleavage (Fig.
7A,B) were detected in the cerebral cortex.
Because the chronic model was capable of reproducing several
important features reported in HD patients such as progressive
and sustained mitochondrial defects, detectable calpain activa-
tion and no major increase in caspase-3 activity, we used this
model to further examine the effects produced by calpain inhibi-
tion in vivo and its relevance to HD pathogenesis.
CI-1 infusion inhibits calpain in vivo
If calpain activity is central to striatal degeneration produced by
sustained mitochondrial defects, inhibiting calpain could have
Figure 7. Calpain activation in acute and chronic 3-NP models. A–C, Homogenates prepared from striatum and cerebral cortex of 3-NP-treated and control (CTRL) rats were analyzed by SDS-PAGE
followed by Western blot for fodrin (known substrate of calpain and caspase-3) and assayed for calpain-dependent proteolytic activity using the fluorogenic substrate N-succinyl-LY-AMC ( D). E,
Western blot analysis of-calpain cleavage in cytosol fractions from striatum and cerebral cortex of 3-NP-treated animals. The typical calpain-dependent cleavage of fodrin appearing as a 145/150
kDa doublet is found in the striatum of both acute ( A) and chronic ( B) 3-NP models (each lane contains pooled samples from 5– 8 animals). Note in A the presence between two nonspecific (N.S.)
bands of a 120 kDa band (asterisk), possibly because of a caspase-3-mediated fodrin breakdown product. In B, chronic 3-NP animals were analyzed every 6 hr showing that the intensity of this
doublet increases on day 4 and is maximal at day 5. Western blots for fodrin in cerebral cortex were slightly overexposed. C shows that the pattern found in the striatum of 3-NP-treated animals (day
5) is clearly different from the caspase-3-mediated cleavage of fodrin observed after in vitro digestion of control samples with recombinant caspase-3 (CTRL R. Casp-3). Note the prominent
increase in the proteolytic activity of calpain and the presence of cleaved/active form of-calpain in the striatum of chronic 3-NP rats, whereas no changes were found within the cerebral cortex of
the same animals. Data are means SEM determined in 5–10 animals. N.D., Not detectable.p 0.0005 compared with control, ANOVA, and post hoc Scheffe´ F test.
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neuroprotective effects. To test this hypothesis, we first examined
whether intracerebroventricular infusion of the selective calpain
inhibitor CI-1 would inhibit calpain in vivo. We first measured
the inhibition of purified -calpain induced by striatal soluble
fractions taken from rats infused by CI-1 (2.5 g/hr for 5 d) or
vehicle. Control samples produced no significant inhibition of
purified -calpain. In contrast, fractions from CI-1-treated ani-
mals significantly inhibited the activity of the purified enzyme by
70% (Fig. 8A).
By measuring the in vitro IC50 value of CI-1 for -calpain
(9.28 nM) and taking into account the various dilution factors
(200-fold) resulting from striatum dissection, homogenization
and the in vitro -calpain assay, we estimated striatal concentra-
tions of CI-1 inhibiting calpain in vivo at 3 M (Fig. 8A). We
then examined whether this dose of CI-1 could effectively prevent
the activation of calpain in vivo and the accumulation of calpain-
dependent 145/150 kDa fodrin breakdown products. On day 5 of
chronic 3-NP treatment, animals receiving CI-1 displayed a sig-
nificant reduction in endogenous calpain activity and in calpain-
dependent fodrin breakdown products compared with control
rats receiving the vehicle alone (Fig. 8B).
Calpain inhibition prevents 3-NP-induced cleavage
of huntingtin
Since Htt is cleaved by caspases and calpains into fragments of
different molecular weights (Kim et al., 2001), we used Western
blot analysis to determine whether calpain activation modified
the pattern of Htt processing observed in vivo during chronic
3-NP administration. Using an antibody directed against the
N-terminal part of the Htt protein, a major band of high molec-
ular weight (300 kDa) corresponding to full-length Htt was
detected in control striatal samples (Fig. 8C), whereas the inten-
sity of this band was decreased at day 5 in the 3-NP-treated ani-
mals. Additionally, striatal samples from 3-NP-treated rats pre-
sented two main immunoreactive bands of 65 kDa and 56 kDa,
corresponding to breakdown products of Htt. Similar bands were
found when control striatal samples were digested with-calpain
in vitro (Fig. 8C). Infusing calpain inhibitor CI-1 in the 3-NP-
treated rats reduced both the decrease in full-length Htt and the
accumulation of these two Htt breakdown products, indicating
that abnormal cleavage of Htt was reduced by intracerebroven-
tricular infusion of CI-1 in vivo.
Calpain inhibition prevents 3-NP-induced striatal cell death
Because CI-1 could block calpain activation and reduce abnor-
mal processing of the wild-type Htt in the chronic model, we next
examined whether CI-1 infusion could prevent 3-NP-induced
striatal neurodegeneration. We evaluated the effects of CI-1 at
day 5 of the chronic 3-NP treatment, at a time of severe striatal
degeneration (Dautry et al., 2000; Ouary et al., 2000; Garcia et al.,
2002; Mittoux et al., 2002). CI-1 markedly reduced the size of
striatal lesions and resulted in cytochrome oxidase levels (a
marker of neuronal integrity) near control values (Fig. 9A–C).
The Cl-1 effects were not caused by a direct interaction of Cl-1
with 3-NP, because the SDH inhibition was similar in vehicle- or
CI-1-treated rats (data not shown). In addition, we analyzed the
effect of CI-1 on DNA fragmentation, a late stage marker of
3-NP-induced neurodegeneration. We showed that CI-1 pre-
vented DNA fragmentation in striatal cells as detected by the
levels of free oligonucleosomes and the number of TUNEL-
positive cells in the striatum (Fig. 9D–F).
Discussion
We used two different animal models of mitochondrial blockade
associated either with transient or sustained complex II inhibi-
tion, and we found that whereas activation of calpain was ob-
served in both conditions, this was not the case for another death
effector protease, caspase-3. In addition, calpain activity was spe-
cifically increased in the striatum, a region known to be specifi-
cally sensitive to both 3-NP-induced degeneration and HD pa-
thology but not in the cerebral cortex. Finally, calpain inhibition
spared striatal cells from neurodegeneration. Together, these
data indicate that calpain activation is essential in 3-NP-induced
striatal cell death. Because a sustained and partial mitochondrial
complex II defect has been reported so far in HD (Brouillet et al.,
Figure 8. Calpain inhibitor I (CI-1) inhibits calpain in vitro and in vivo. A, Ex vivo estimation of
the inhibiting effects of intracerebroventricular infusion of CI-1 (2.5g/hr for 5 d) on calpain.
Left panel, Striatal cytosol fractions from control (open bar) or 3-NP-treated rats infused with
CI-1 (gray bar) were incubated with purified-calpain before measuring the enzyme activity in
vitro. Right panel, Inhibition curve of purified-calpain by CI-1 in vitro (IC50 9.28 nM). B, Top
panel, SDS PAGE followed by Western blot for fodrin in striatal membrane fraction prepared
from chronic 3-NP-treated and CTRL rats. Note that CI-1 compared with its vehicle (VEH) mark-
edly inhibits in vivo the 3-NP-induced accumulation of the calpain-mediated 145/150 kDa
breakdown products of fodrin. Bottom panel, Reduction of the activity of endogenous calpain
by infusion of CI-1 in 3-NP-treated rats. C, SDS-PAGE followed by Western blot for huntingtin
(Htt) of striatal samples from control (CTRL) or rats treated with 3-NP for 5 d (3-NP). Samples of
CTRL rats were loaded after incubation with or without-calpain or with or without caspase-3
(R. Casp-3). 3-NP-treated rats received calpain inhibitor 1 (CI-1) or its vehicle only (VEH). The
3-NP treatment induces a reduction of full-length Htt concentrations and the appearance of Htt
breakdown products (56 and 65 kDa, arrows) which are similar to those observed after in vitro
cleavage of control striatum samples by-calpain. Note that in vivo treatment with CI-1 pre-
vents the effects of 3-NP toxicity. N.D., Not detectable.p 0.002, Student’s t test.
5026 • J. Neurosci., June 15, 2003 • 23(12):5020 –5030 Bizat et al. • Calpain and HD-Like Mitochondrial Defects
1999), these data also strongly support a direct implication of
calpain in HD pathogenesis.
Using a number of biochemical and immunocytochemical
evidence, we have shown that caspase-9, -8, and -3 are all acti-
vated in the model of transient mitochondrial inhibition. In this
situation, the activation of caspase-3 may result from the cleavage
of its zymogen form by upstream caspase-9 and/or caspase-8, and
this is consistent with our observations that upstream caspase-8
and -9 activation precedes caspase-3 activation in the striatum
after acute 3-NP treatment. Although activation of caspase path-
ways is well known to occur in cell culture models of energy
compromise (Du et al., 1997; Leist et al., 1998; Hartmann et al.,
2000; Ohgoh et al., 2000; Newcomb-Fernandez et al., 2001), our
data suggest that acute 3-NP toxicity in vivo may involve molec-
ular actors of apoptosis as well. In agreement with our present
findings, activation of caspase-3 has been observed in vivo under
experimental conditions associated with transient mitochondrial
perturbation such as focal ischemia (Namura et al., 1998; Bench-
oua et al., 2001), intrastriatal injection of the 3-NP analog mal-
onate (Schulz et al., 1998), or subacute repeated injections of
3-NP (Duan et al., 2000; Kim et al., 2000).
In clear contrast with the findings in the acute model, we
found no activation of caspase-8 during chronic 3-NP treatment.
Despite an activation of caspase-9, no caspase-3 activation was
detected. The reasons for this are unclear. One hypothesis is that
the spreading out of apoptotic events in the chronic model evolv-
ing over 5 d would not have allowed us to detect caspase-8 and -3
activation. Although we cannot completely rule out this possibil-
ity, the spreading out of apoptotic events would similarly impede
detecting caspase-9 activation in the chronically treated rats. A
more likely explanation is that specific molecular events may
preclude caspase-3 activation and/or the accumulation of active
forms of caspase-3 in the chronic model. One possibility is that
caspase-9 activation leads to caspase-3 processing but that the
rate of degradation of the active forms of caspase-3 is accelerated
in this model, preventing the accumulation of functional forms
of the death effector protease. In favor of this hypothesis, prelim-
inary data obtained in vitro and in vivo using the chronic 3-NP
model show that processed caspase-3 can be degraded by calpain
(N. Bizat, J.-M. Hermel, P. Hantraye, S. Krajewski, and E. Brouil-
let, unpublished observations). Additional studies will be needed
to understand the absence of processed forms of caspase-3 in the
chronic 3-NP model.
Regardless of the precise mechanisms of caspase-3 regulation,
our data demonstrate that one mitochondrial toxin may activate
different cell death mechanisms, depending on the pattern of
acute and chronic mitochondrial perturbation. Our data also
suggest that increased caspase-3 processing may not be strictly
required for 3-NP to produce striatal degeneration. This absence
of “pathological” caspase-3 processing in the chronic model is
reminiscent of the absence of abnormal caspase-3 processing ob-
served in HD patients and in transgenic mice models overex-
pressing the full-length Htt protein. In line with this, whereas
neurotoxicity of quinolinate in wild-type rodents in vivo seems to
require caspase-3 processing (Qin et al., 2000), quinolinate tox-
icity in transgenic YAC72 mice overexpressing a full-length mu-
tated Htt is not associated with an increased caspase-3-mediated
cleavage of Htt (Zeron et al., 2002). However, the toxicity of the
mutated Htt requires the presence of caspases (Saudou et al.,
1998; Sanchez et al., 1999), probably for cleavage of full-length
Htt into shorter and more toxic fragments (Wellington et al.,
2002). In a number of physiological forms of cell death, increased
processing of effector caspases, especially caspase-3 is observed
(Nicholson and Thornberry, 1997). For Htt toxicity in HD, the
role of caspase pathways may not necessarily be associated with
increased caspase processing. The results from the chronic 3-NP
model suggest that the striatal cell death resulting from mito-
chondrial defects in HD patients may not require abnormal
caspase activation and that other death effector proteases are im-
plicated in the disease process.
A novel finding of the present work is that the cysteine pro-
tease calpain is the essential cell death effector in 3-NP-induced
HD-like pathogenesis. In the mammalian brain, calpains (-
Figure 9. Calpain inhibition protects the striatum against chronic 3-NP toxicity. Control rats
(CTRL) and rats treated for 5 d with 3-NP received continuous infusion of CI-1 or its vehicle (VEH).
A, Representative coronal brain sections stained for cytochrome oxidase histochemistry: 3-NP-
treated rats that received vehicle showed severe striatal neurodegeneration (open arrow),
which is reduced by CI-1 treatment. B, Quantification of the 3-NP-induced striatal lesion vol-
ume. C, Quantification of cytochrome oxidase activity. D, ELISA quantification of oligonucleo-
somes (DNA fragmentation) in the cytosol prepared from the striatum of CTRL and 3-NP-treated
rats with or without CI-1 treatment. E, Localization of striatal neurons with DNA fragmentation
(TUNEL-positive cells) on coronal sections from 3-NP-treated rats. Section from the CI-1-treated
animal with the highest TUNEL-positive cell density is shown. F, Quantification of striatal
TUNEL-positive neurons in 3-NP-treated animals. Data are means SEM measured in six or
seven animals.p 0.005, two groups comparison using unpaired Student’s t test (B, F ) or
p 0.002 compared with CTRL using ANOVA and post hoc Scheffe F test (C, D).
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calpain and m-calpain) are present as heterodimers (catalytic 80
kDa subunit and regulatory 30 kDa subunit) in the cytosol and
are activated by increases in Ca 2 concentrations (Chan and
Mattson, 1999; Wang, 2000). In the present study, calpain activity
was increased by 3-NP in conditions of both transient and sus-
tained inhibition of the respiratory chain. Results from Western
blot analysis suggest that in the chronic 3-NP model this activa-
tion involves-calpain. It has been shown that once activated by
micromolar concentrations of Ca 2,-calpain can itself activate
m-calpain through a “heterolytic” processing (Tompa et al.,
1996). Thus, it is likely that m-calpain is also activated by 3-NP,
although additional studies are required to precisely examine this
point. Additionally, we demonstrated a calpain-dependent de-
crease in full-length Htt, coincident with the appearance of Htt
breakdown products in the striatum of 3-NP-treated rats. Finally,
the present data show that calpain activation in vivo likely plays a
central role in 3-NP toxicity because pharmacological inhibition
of the protease produces significant neuroprotective effects
against neurotoxin effects.
The mechanisms underlying the “pathological” activation of
calpain in 3-NP-treated animals remain speculative but probably
involve alterations in Ca 2 homeostasis. Although we show that
3-NP produces a partial blockade of SDH/complex II in our
models, further studies will be necessary to characterize in vivo
the early consequences of this blockade on mitochondrial mem-
brane potential, radical oxygen species production, Ca 2 uptake
capacity, oxidative phosphorylation, and general cellular energy
charge. However, it is likely that ATP concentrations are not
profoundly modified in the 3-NP models at time points preced-
ing overt tissue damage because (1) we observed caspase-9 acti-
vation, which is an ATP-dependent process, and (2) we previ-
ously showed increased phosphorylation of the c-jun N-terminal
kinase in the chronic model (Garcia et al., 2002). One interesting
hypothesis is that the 3-NP-induced partial blockade of SDH may
reduce the capacity of mitochondria to regulate cytosolic Ca 2
concentrations. Interestingly, Ca 2 entering through NMDA re-
ceptors is tightly regulated by mitochondrial reuptake system in
neurons (Peng and Greenamyre, 1998). Thus, it is possible that
once SDH is partially inhibited by 3-NP, the pool of cytosolic
Ca 2 associated with physiological NMDA receptor activation
may be inefficiently regulated by mitochondria leading to a rise in
cytosolic Ca 2 concentrations. As shown previously in brain
slices and neurons in culture, at concentrations that do not
increase cytosolic Ca 2 per se, 3-NP markedly potentiates the
rise in Ca 2 produced by NMDA receptor stimulation in stri-
atal medium-size spiny neurons (Greene et al., 1998; Calabresi
et al., 2001). Several studies in cell culture or in rats also sup-
port an important role of NMDA receptors in 3-NP toxicity
(Beal et al., 1993; Simpson and Isacson, 1993; Wu¨llner et al.,
1994; Zeevalk et al., 1995). However, it cannot be ruled out
that 3-NP produces at least in part, Ca 2 changes indepen-
dently of NMDA receptors. Other pools of Ca 2 may be also
affected such as the pool of the endoplasmic reticulum. An
excess of intracellular Ca 2 could activate calpain, leading to
cleavage of specific substrates important for cell survival, and
eventually cell death.
The presence of activated calpain in the striatum of rats with
chronic mitochondrial deficits is highly reminiscent of the mod-
ifications observed recently in HD patients (Gafni and Ellerby,
2002). HD patients have an increase in the activated calpain, as
revealed by the presence of cleaved 30 kDa regulatory subunit on
Western blot and upregulation of - and m-calpain in the cau-
date nucleus as seen by immunohistochemistry. In addition, the
calpain-dependent cleavage of Htt is increased in the caudate of
HD patients (Kim et al., 2001; Gafni and Ellerby, 2002). Our
results showing that 3-NP can indirectly activate calpain in vivo
are, to our knowledge, the first demonstration that calpain ab-
normalities in HD could directly result from the chronic mito-
chondrial defects that have been consistently observed in HD
patients (Jenkins et al., 1993, 1998; Gu et al., 1996; Browne et al.,
1997; Sawa et al., 1999; Tabrizi et al., 1999; Panov et al., 2002).
The present results also demonstrate that calpain activation is
region-selective, which could explain the preferential vulnerabil-
ity of the striatum for 3-NP-induced chronic mitochondrial in-
hibition. Whereas systemic 3-NP administration produces an
ubiquitous inhibition of SDH activity in the brain (Brouillet et al.,
1998; Garcia et al., 2002), calpain activation was only observed in
the striatum and not in other brain regions, less vulnerable to the
neurotoxin such as the cerebral cortex. One possibility for ex-
plaining a region-specific activation of calpain is that for a similar
level of 3-NP-induced SDH inhibition, changes in intracellular
Ca 2 concentrations are higher within striatal projection neu-
rons compared with less vulnerable cells, such as cortical neu-
rons. Alternatively, 3-NP may increase Ca 2 in many brain re-
gions, whereas calpain in striatal neurons may be particularly
susceptible to activation by Ca 2. Possible contributing factors to
such a susceptibility might include regional differences in sub-
strates and inhibitors and/or regulation of expression of the pro-
tease. Whether such a striatal-selective activation of calpain also
occurs in HD awaits further study.
The results of the chronic 3-NP model also suggest the exis-
tence of a vicious circle in which mitochondrial defects in HD
could amplify the toxic effects of mutated Htt. Mitochondrial
defects resulting from Htt mutation may lead to anomalies in
Ca 2 homeostasis (possibly at the level of pools of Ca 2 associ-
ated with NMDA receptors) and “uncontrolled” calpain activa-
tion. This would in turn increase cleavage of full length Htt.
Given that wild-type Htt is neuroprotective against mutated Htt
(Cattaneo et al., 2001), this would render striatal cells more vul-
nerable to mutated Htt. In addition, the increased calpain-
mediated cleavage of mutated Htt may generate shorter N termi-
nus fragments containing the toxic polyglutamine stretch.
Because it has been shown that for a given polyglutamine length
(higher than 37), the shorter the fragment, the higher the toxicity
(Hackam et al., 1998), the activation of calpain would amplify the
toxic effects of mutated Htt. Finally, in addition to the amplifica-
tion of Htt toxicity, high levels of activated calpain may directly
lead to cell death through proteolysis of other calpain-sensitive
neuronal proteins.
It is possible that the mitochondrial perturbation-induced
calpain activation may be also involved in other neurodegenera-
tive disorders such as Alzheimer’s disease (Chan and Mattson,
1999; Lee et al., 2000), which has been associated with secondary
mitochondrial defects (Beal, 2000). In this context, it has been
hypothesized that calpain blockade in neurodegenerative dis-
eases may be of therapeutic interest (Di Rosa et al., 2002). Sup-
porting this view, we demonstrate that calpain blockade produces
a significant neuroprotection including drastic reduction of DNA
fragmentation in the chronic 3-NP model of HD.
In conclusion, the present study points to calpain as one of the
major actors of cell death process in HD and strongly supports
the hypothesis that inhibiting calpain activity is a potential ther-
apeutic strategy for the treatment of HD and possibly other neu-
rodegenerative disorders.
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